Abstract: A seal for sealing an interface between a piston shaft (4) of an expander mechanism for a disk brake and an inner surface of a housing (5) of the brake in which the shaft is received is described. The seal comprises: a laterally outwardly disposed portion (11) adapted to engage a portion of the housing in fixed relation therewith; a laterally inwardly disposed portion (12) which is adapted to form a static seal with a surface of the shaft; and an intermediate portion (13) interconnecting said laterally outwardly disposed portion (11) and said laterally inwardly disposed portion (12) such that the laterally inwardly disposed portion is permitted to move axially together with the shaft relative to the laterally outwardly disposed portion, in use, in static sealing relationship with the shaft.

Abstract: The present invention discloses a system and method for improving the organization and dissemination of information in a management information system (MIS). Improved security, organization and delivery of data is achieved in an MIS through the creation of a number of novel databases and an associated method of utilization whereby outside suppliers are provided with timely and secure access to drawing information stored at the MIS. In accordance with the novel data organization and dissemination methods of the invention, the MIS is assured that vendors will have a capability to only view drawings and related information which pertain to the particular vendor thereby preventing the vendor from viewing and/or accessing other vendor's information.

Abstract: A method is provided for administering to a mammal suffering from, or at risk for, multiple sclerosis, an initial dosing of a therapeutically effective amount of an anti-LFA-1 antibody, followed by a subsequent intermittent dosing of a therapeutically effective amount of the anti-LFA-1 antibody wherein the antibody is administered to the mammal no more than once per week in the intermittent dosing.

Abstract: A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.

Abstract: A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam, or a pharmaceutically acceptable salt thereof, delivered as an aerosol or dry powder formulation.

Abstract: A seal for sealing an interface between a piston shaft (4) of an expander mechanism for a disk brake and an inner surface of a housing (5) of the brake in which the shaft is received is described. The seal comprises: a laterally outwardly disposed portion (11) adapted to engage a portion of the housing in fixed relation therewith; a laterally inwardly disposed portion (12) which is adapted to form a static seal with a surface of the shaft; and an intermediate portion (13) interconnecting said laterally outwardly disposed portion (11) and said laterally inwardly disposed portion (12) such that the laterally inwardly disposed portion is permitted to move axially together with the shaft relative to the laterally outwardly disposed portion, in use, in static sealing relationship with the shaft.

Abstract: A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam, or a pharmaceutically acceptable salt thereof, delivered as an aerosol or dry powder formulation.

Abstract: A method is provided for administering to a mammal suffering from, or at risk for, a LFA-1-mediated disorder an initial dosing of a therapeutically effective amount of LFA-1 antagonist, followed by a subsequent intermittent dosing of a therapeutically effective amount of LFA-1 antagonist that is less than 100%, calculated on a daily basis, of the initial dosing of antagonist.

Abstract: A data card is reduced in size from the conventional standard size credit card. Accessibility of the card is enhanced because the card may be stored in a separate location from conventionally sized cards, such as on a key-chain or similar device. The card of the present invention has a means for storing information, such as a magnetic stripe or computer chip.

Abstract: A data card is reduced in size from the conventional standard size credit card. Accessibility of the card is enhanced because the card may be stored in a separate location from conventionally sized cards, such as on a key-chain or similar device. The card of the present invention has a means for storing information, such as a magnetic stripe or computer chip.

Abstract: A data card is reduced in size from the conventional standard size credit card. Accessibility of the card is enhanced because the card may be stored in a separate location from conventionally sized cards, such as on a key-chain or similar device. The card of the present invention has a means for storing information, such as a magnetic stripe or computer chip.

Abstract: A method for treatment, prevention and containment of acute and chronic tuberculosis using a preservative-free concentrated tobramycin aerosol formulation delivering tobramycin to the lung endobronchial space including alveoli in an aerosol having mass medium average diameter predominantly between 1 to 5.mu.. The method comprises administration of tobramycin in concentration one to ten thousand times higher than the minimal inhibitory concentration of Mycobacterium tuberculosis. A method for containment of and decreasing infectivity periods of tuberculosis patients to shorter periods of time.

Abstract: An anti-Pseudomonas aeruginosa agent which is substantially pure biologically active colistin, its component, a mixture thereof or a pharmaceutically acceptable salt thereof delivered as an aerosol or dry powder formulation. A formulation and method for preparation of substantially pure biologically active colistin, its components, mixtures thereof and a pharmaceutically acceptable salts thereof. A method for treatment and prophylaxis of Pseudomonas aeruginosa, Stenotrophomonas maltophilia or other susceptible pulmonary bacterial infections.

Abstract: A method is provided for administering to a mammal suffering from, or at risk for, a LFA-1-mediated disorder an initial dosing of a therapeutically effective amount of LFA-1 antagonist, followed by a subsequent intermittent dosing of a therapeutically effective amount of LFA-1 antagonist that is less than 100%, calculated on a daily basis, of the initial dosing of antagonist.